A whole-body MRI has been mostly a boutique experience. Fitnescity Health, which calls itself the largest US network of ...

Formerly Kesmalea, the London company says its degraders cross the blood-brain barrier in pieces, then self-assemble on the other side.

New data covers the Wegovy pill in real life, an investigational drug at lower doses, and children as young as six.

GSK and Alamar will profile more than 60,000 serum samples to see how one diagnosis can hide several diseases.

Eisai’s CTAD slate includes five-year Clarity AD data, a real-world symposium and a look at lecanemab and donanemab dosing.

From brain scans to Super Mario, NeuroAge and TruDiagnostic explain how Younger turns personal health goals into public ...

Built with David Sinclair for Grok Bot, the free multi-agent system turns personal health data into checkable N-of-1 experiments.

Ultrahuman’s racing partnership is about more than lap times; the bigger story is the teenage years when female healthspan takes shape.

SIR2501, a SARM1 blocker with FDA Fast Track status for chemo nerve damage, gets three poster slots in Washington.

A late-breaking slot in Boston will bring fresh data on an experimental drug that aims to turn down tau production in the ...

Six-month University of Surrey RCT sees better endothelial function, less arterial stiffness and lower systolic pressure – but lipids unmoved. Professor Christian Heiss and his University of Surrey ...

Alamar and Nightingale will hunt rare, low-level proteins in UK Biobank blood for signs of dementia and Parkinson’s long before diagnosis. The proteins that give the earliest warning of a failing ...